P-tau (specifically tau phosphorylated on threonine 181, p-tau181) has been described as a more specific biomarker for AD since p-tau is present at normal levels in most other neurodegenerative disorders, but not in AD [29]. Here, MAPT is linked to Alzheimer disease.